An increasing amount of evidence suggests that inactivated STK11 somatic mutations contribute to the pathogenesis of numerous cancers, such as gastrointestinal cancer [4], non-small cell lung cancer (NSCLC) [5–7], pancreatic cancer [8], cervical cancer [9, 10], and melanoma [11], which are influenced by inactivated STK11 somatic mutations. This evidence concerns the gene STK11 and pancreatic neoplasm.